Ubidecarenone is under clinical development by Berg and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ubidecarenone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ubidecarenone overview

Ubidecarenone is under development for sarcopenia, metastatic pancreatic adenocarcinoma, squamous cell carcinoma, breast cancer, refractory solid tumor, brain cancer, lymphoma, epidermolysis bullosa, recurrent high-grade glioma, anaplastic astrocytoma, gliosarcoma, and glioblastoma multiforme. The drug candidate is administered through topical and intravenous infusion routes. Ubidecarenone is a naturally occurring coenzyme structurally similar to vitamin K. The drug candidate is developed by interrogative biology platform.

It was also under development for the treatment of liver cancer, lupus, wounds, skin cancer, chemotherapy effects, leukemia, basal cell carcinoma and third line therapy of gastric cancer, colon cancer, kidney cancer (renal cell cancer), head and neck cancer, non-small cell lung cancer, malignant mesothelioma, bladder cancer.

Berg overview

Berg is a clinical-stage, artificial intelligence-powered biotechnology company. Its pipeline products include BPM 31510 and BPM 31543. The company’s proprietary platform Interrogative Biology combines patient biology and artificial intelligence-based analytics to understand predictive patterns on diseases. Berg’s carries out research and development of diagnostics, theranostics and patient therapeutics in the areas of oncology, endocrinology and neurology. Its analytics engine enables health plans, electronic health records vendors, providers, and clinical decision support organizations to plan, implement and measure interventions. The company partners with pharmaceutical, healthcare, academic and government organizations to provide innovative healthcare solutions. Berg is headquartered in Framingham, Massachusetts, the US.

For a complete picture of Ubidecarenone’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.